Cerevel Therapeutics Inc (CERE) - Forward Price-to-Revenue Multiple

Cerevel Corp (CERE) - corporate logo

Cerevel Therapeutics (CERE) develops targeted molecules to combat Alzheimer's and schizophrenia. The brand solidified its status as a reliable clinical leader following its acquisition by a pharma behemoth. High R&D potential is focused on receptor bioengineering for Parkinson's disease. The projected P/S dynamics on the GURU.Markets terminal linear chart visualize the business valuation, where reflects the most recent value of the metric.

cerevel.com - CERE Forward Price to Sales (period 07/04/2022 - 11/15/2026)

Comprehensive metric breakdowns and analytics for Cerevel Therapeutics (CERE)

- stock price and consensus target price:
Fundamental company analysis:CERE (Cerevel Therapeutics, Inc.)
Original product of Cerevel Corp

The forward P/S ratio assesses the market value of a company relative to its expected revenue, allowing investors to determine the degree of asset overvaluation amid a potential decline in demand. By analyzing the projected P/S multiple, one can evaluate the fair value of Cerevel Therapeutics (CERE), whose diversified development of neuropsychiatric drugs across various trial stages minimizes the risk of capital stagnation while awaiting the commercialization of its pipeline.

Direct competitors

Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Price-to-Projected Revenue Ratio|AVXL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CeriBell|Forward P/S Multiple Prothena Corporation plc|Price-to-Projected Revenue Ratio Alector Therapeutics (ALEC)|Annexon Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio omeros.com OMER|neurogene.com (NGNE) - Market Cap to Future Revenue Ratio|acimmune.com - Forward P/S Multiple|Voyager Therapeutics Inc (VYGR) - Forward Price-to-Revenue Multiple|Neumora Corp (NMRA) - Price-to-Projected Revenue Ratio|Scilex Holding Company, Inc. (SCLX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TVGN|Market Cap to Future Revenue Ratio Alpha Cognition Inc. ACOG|Price-to-Projected Revenue Ratio cogrx.com (CGTX)|Market Cap to Expected Sales Ratio Inhibikase Therapeutics, Inc.|Forward P/S Multiple SAVA (Cassava Sciences Inc)|Forward P/S Multiple Assertio Holdings, Inc. ASRT|COYA - Price-to-Projected Revenue Ratio|Projected Price to Revenue Vistagen (VTGN)|OVID: Forward P/S Multiple|Market Cap to Future Revenue Ratio Acumen Pharmaceuticals Inc. (ABOS)|Forward Price-to-Revenue Multiple CRVO|Market Cap to Projected Revenue ATHE (Alterity Therapeutics)|Price-to-Projected Revenue Ratio Clene Nanomedicine (CLNN)|PEPG (PepGen) - Forward Price to Sales|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|Forward Price to Sales RLMD|ANVS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Grace Therapeutics Inc|AIFF: Forward P/S Multiple|Market Cap to Future Revenue Ratio Klotho Neurosciences Inc (KLTO)|Price-to-Projected Revenue Ratio neurosense-tx.com|Market Cap to Future Revenue Ratio Reviva Pharmaceuticals Holdings Inc. RVPH|Price-to-Projected Revenue Ratio MetaVia Inc. (MTVA)|Market Cap to Expected Sales Ratio NeurAxis Inc|Forward P/S Multiple HSDT (heliusmedical.com)|Forward Price to Sales PASG|NEUP: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Minerva Neurosciences Inc|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Addex Therapeutics, Ltd. - Forward Price to Sales|ALZN (Alzamend Neuro) - Forward P/S Multiple|Market Cap to Future Revenue Ratio cyclerion.com CYCN|Forward P/S Multiple PTIX|KTTA - Market Cap to Future Revenue Ratio|Forward P/S Multiple CRGT (Cortigent, Inc.)|Avenue Therapeutics Inc (ATXI) - Market Cap to Future Revenue Ratio|BCLI - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio caratherapeutics.com|CHRO: Forward P/S Multiple|Market Cap to Future Revenue Ratio Eliem Therapeutics (ELYM)|ITCI (Intra-Cellular Therapies Inc.) - Forward P/S Multiple|Forward P/S Multiple Longboard|Forward P/S Multiple MRNS|Market Cap to Expected Sales Ratio nkgenbiotech.com|Forward P/S Multiple NRBO (neurobopharma.com)|Sage Therapeutics, Inc (SAGE) - Market Cap to Future Revenue Ratio|SNPX - Price-to-Projected Revenue Ratio|Forward Price to Sales TRVN (Trevena, Inc)|VIGL: Forward P/S Multiple|Market Cap to Future Revenue Ratio anewmeds.com (WENA)